In the above-mentioned multi-arm phase 2 trial (NCT02523014) of patients with progressive NF2-altered meningioma, capivasertib has been included as one of four experimental treatments for patients with AKT mutant meningiomas. The gene discussed is AKT1; the disease is meningioma.